Good morning :)
$
₹
HUTCHMED DRC

HUTCHMED DRC

HCM

NASDAQ
Asset Logo

HUTCHMED DRC

HCM

NASDAQ
$14.360% (-)
$
₹
$14.360% (-)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Mid Cap

With a market cap of $2.5B the stock is ranked 1999

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

143.6
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.25
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.1
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

3.26%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 12 analysts reports

Buy
10 analysts
Hold
2 analysts
Sell
0 analyst

Price Upside

+43.39%

Earnings Growth

—

Rev. Growth

+13.94%

See Detailed Forecast

Company Profile

Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
42.74
42.74
1Y Return
55.33%
55.33%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
40.03
40.03
1Y Return
37.93%
37.93%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
115.29
115.29
1Y Return
66.63%
66.63%
Buy Reco %
70.37
70.37
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
22.82
22.82
1Y Return
14.79%
14.79%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
25.78
25.78
1Y Return
1.93%
1.93%
Buy Reco %
83.33
83.33
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 43.39% growth, versus a trailing 3-year CAGR of -4.96%.

2026
Current$14.36Baseline
Analyst Target - 1 year
Target$20.59+43.39%

All values in $

202220232024202520262027$14.66$17.32$19.99Target+43.39%
2026
Current$14.36Baseline
Analyst Target - 1 year
Target$20.59+43.39%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 13.94% growth, versus a trailing 3-year CAGR of 8.85%.

2025
Current$549.96Baseline
Forecast for Dec 2026
High$727.35+32.26%
Average$626.60+13.94%
Low$570.03+3.65%

All values in $ Million

202120222023202420252026356.12426.40837.99630.20549.96Low+3.65%Average+13.94%High+32.26%
2025
Current$549.96Baseline
Forecast for Dec 2026
High$727.35+32.26%
Average$626.60+13.94%
Low$570.03+3.65%

All values in $ Million

Financials

Financials

Income

Balance Sheet

Cash Flow

135.4
0.9
135.4
0.9
139.1
7.9
139.1
7.9
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue152.84152.84162.26162.26138.83138.83135.41135.41139.14139.14
Net Income12.9012.905.965.96227.47227.470.970.977.967.96
Net Profit Margin8.44%8.44%3.67%3.67%163.84%163.84%0.72%0.72%5.72%5.72%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
HUTCHMED DRC 143.62.250
Eli Lilly and Company42.7430.781.15
Johnson & Johnson40.037.632.82
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare HCM with any stock or ETF
Compare HCM with any stock or ETF
Comparing from
HCM
LLY
JNJ
Loading...

Frequently asked questions

  1. HUTCHMED DRC (HCM) share price today is $14.36 as of October 27, 2026 at 12:02 AM IST. The stock touched a day high of $14.58 and a day low of $14.30.

  2. HUTCHMED DRC stock trades on NASDAQ under the ticker symbol HCM.

  3. HUTCHMED DRC's market capitalization is $2.49B as of October 27, 2026 at 12:02 AM IST.

  4. HUTCHMED DRC's price-to-earnings (P/E) ratio is 143.6 as of October 26, 2026.

  5. HUTCHMED DRC's price-to-book (P/B) ratio is 2.25 as of October 26, 2026.

  6. Yes, You can buy HUTCHMED DRC shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy HUTCHMED DRC shares in three steps: 1. Search HUTCHMED DRC on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since HUTCHMED DRC trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in HUTCHMED DRC (HCM) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.6963 shares at the current price of $14.36.

Loading...